Musashi1 Promotes Non-Small Cell Lung Carcinoma Malignancy and Chemoresistance via Activating the Akt Signaling Pathway | Zendy

Yaoguo Lang | Zendy; Xianglong Kong | Zendy; Changjun He | Zendy; Fengjiao Wang | Zendy; Benkun Liu | Zendy; Shibo Zhang | Zendy; Jinfeng Ning | Zendy; Kaibin Zhu | Zendy; Shidong Xu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Musashi1 Promotes Non-Small Cell Lung Carcinoma Malignancy and Chemoresistance via Activating the Akt Signaling Pathway

Author(s) -

Yaoguo Lang,

Xianglong Kong,

Changjun He,

Fengjiao Wang,

Benkun Liu,

Shibo Zhang,

Jinfeng Ning,

Kaibin Zhu,

Shidong Xu

Publication year - 2017

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000485012

Subject(s) - protein kinase b , lung cancer , cancer research , malignancy , cell growth , microrna , cancer , medicine , pi3k/akt/mtor pathway , signal transduction , carcinoma , blot , biology , oncology , gene , microbiology and biotechnology , biochemistry , genetics

Lung cancer is one of the leading causes for cancer mortality. The poor therapeutic outcome of non-small cell lung carcinoma (NSCLC) is mainly due to late diagnosis and chemoresistance. In this study, we investigated the role of Musashi1 (MSI1) in NSCLC malignancy and chemoresistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research